On-Demand CGT Formulation Webinars

  1. Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles 4/25/2024

    The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?

  2. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

    mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

  3. mRNA LNP Scale Up For GMP Vaccine Production 4/14/2022

    Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.

  4. Democratizing RNA Nanotherapeutics 4/14/2022

    This webinar is presented by Dr. John P. Cooke, Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center.

  5. Polysarcosine-Functionalized LNPs For Therapeutic mRNA Delivery 4/14/2022

    Discover how polysarcosine-functionalized lipid nanoparticles are transforming mRNA delivery. Join Dr. Heinrich Haas of BioNTech as he unveils innovative research and its implications for therapeutic breakthroughs.

  6. RNA Vaccine Development To Phase I 4/14/2022

    Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.

  7. DNA Vaccine Development In A Global Pandemic: A Personal Account 4/14/2022

    Dr. Gerrit Borchard, University of Geneva, presents a personal account of DNA vaccine development in a global pandemic.

  8. Scale Up And Manufacturing Of RNA-LNPs For A COVID-19 Vaccine 4/13/2022

    Dr. Jason Coleman, Clinical Application Scientist Lead with Precision NanoSystems, presents on an overview of the development and scale-up activities needed to progress this saRNA vaccine to the clinic.

  9. Molecular And Colloidal Ionization Properties Of Lipid Nanoparticle mRNA Vaccines 4/13/2022

    Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.

  10. Strategies For Scaling Up mRNA Manufacturing 4/11/2022

    The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.